PUBLISHED DATE : Jan 2023 | Pages : 306
Fill out your details & get your free sample
The Biosimilar Contract Manufacturing Market Size, Share, & Trends Analysis Report By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027
306 Pages
100 Tables
168 Charts
5 Regions
19 Countries
25 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 5.56 Billion |
| Market Size (2021) | USD 2.26 Billion |
| CAGR (2021-2027) | 16.19% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| SEGMENTS | Source, Scale of Operation, Product, Indication, and Geography |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | Lonza, Catalent, Thermo Fischer Scientific, FUJIFILM, and Boehringer Ingelheim International GmbH |
The global biosimilar contract manufacturing market crossed USD 2.26 billion in 2021 and is expected to reach USD 5.56 billion by 2027, growing at a CAGR of 16.19% from 2021-2027. More than 2 billion people worldwide cannot afford life-saving medicines, putting their lives at risk. Producing potentially life-saving drugs that are more accessible and affordable can help today's patients live better lives for a prolonged period and minimize health inequality. Biologic drugs are at the forefront of therapeutic developments, but their high cost accounts for a significant portion of public and private drug expenditure. Comparatively, biosimilars are an equivalent effective drug at an affordable price, offering the promise of a more sustainable solution. As a result, the biosimilar market continues to post massive growth across all regions worldwide. Since 2015, the biosimilars market has been growing at a CAGR of more than 50%, and the future looks even better, with several favorable factors supporting its high growth. The increasing acceptance of biosimilars in treating diseases, such as autoimmune diseases, cancer, and blood disorders, coupled with the low cost of biosimilars compared to branded biologics, are some of the major factors driving the market.
With the increasing demand for biosimilars, rise in approved biosimilars, and robust pipeline, the demand for outsourcing biosimilars manufacturing is also equally increasing. As a result, many pharma and biotech companies outsource biosimilar R&D and manufacturing to CMOs & CDMOs, which propel the biosimilar contract manufacturing market growth. Outsourcing biosimilar manufacturing enables pharma/biotech companies to reach the market early, free up their resources and manufacturing facilities, focus more on their core businesses and minimize the costs of their drugs. As a result, the CMOs industry is witnessing remarkable growth during the last decade and is expected to continue an even better growth trajectory in the coming years. The CMOs industry is undergoing a paradigm shift. Off-late CMOs are no longer working as just a one-off manufacturing option but have become an integral part of the supply chain of pharma/biotech companies.
In the beginning, major pharma companies continue to be significant contributors to the growth of the biopharma contract manufacturing market; contributions from biotechnology & life sciences companies also increasing in recent years, especially when the demand for biologics, including biosimilars, is at an all-time high worldwide. With the market entry of many biotech companies, there will be greater demand for contract manufacturing services in biologics, including the biosimilars market. Outsourcing the manufacturing function will enable biotech firms to introduce their products in the market without investing in building or upgrading their manufacturing units. As the costs of biosimilars must be kept significantly low, it makes sense for drug developers to outsource manufacturing activities to keep costs low. As a result, CMOs are witnessing healthy growth in their business from the biosimilar contract manufacturing market.
The demand for contract manufacturing services is gaining momentum owing to the increase in investments by big pharma companies for the R&D of various biologics and biosimilars. Moreover, the significant advantage of the reduction in overall investment for developing and manufacturing drugs with contract manufacturing is expected to increase the adoption of contract manufacturing services by pharma/biotech companies in the coming years. Leading CMOs are expanding their existing manufacturing capacities to maintain their strong position in the biosimilar contract manufacturing market. For instance, in April 2018, Catalent Pharma Solutions completed a USD 5.5 million expansion program at its 200,000+ square foot Philadelphia, Pennsylvania manufacturing site to provide additional clinical packaging and storage capacity.
The Rise in Product Launches & Approvals of Biosimilars
The growing number of recent launches in biosimilars are demonstrating a wide range of uptake depending on the molecule and the geography. North America and Europe have accounted for the highest volume of global biosimilar volume; however, greater volume growth rates are expected in the major Asian markets, Southeast Asia, Latin America, and Australasia, in the next decade.
The first biosimilar approved by the US FDA was Sandoz's Zarxio in 2015. Later in 2020, there was a decrease in the annual number of biosimilars approved in the US. In 2019, FDA approved a record-breaking ten biosimilars. But in 2020, FDA only approved three new biosimilars. Additionally, few biosimilars entered the market in 2020, with five being launched compared to seven in 2019. By 2022, the FDA approved 33 biosimilars, of which 21 are available on the US market. In China, a significant surge in the approvals of biosimilars was witnessed from 2018 to 2021, with 13 new biosimilars being approved. The latest regulation changes and biosimilar pipeline will likely drive the biosimilar industry. The demand for biosimilars will constantly be growing due to the rising number of inflammatory and autoimmune diseases. This has been further favored by the patent expirations of the blockbuster biologic drugs, which are highly expensive compared to the highly cost-effective biosimilars. This will further increase the demand for outsourcing the manufacture of biosimilars and contribute to the biosimilar contract manufacturing market's growth.
Patent Expirations of Blockbuster Branded Biologic Drugs
The first 17 blockbuster drugs with annual peak sales reaching USD 60 billion will likely lose exclusivity between 2020 and 2025, creating a market entry of many novel biosimilars. The uptake of biosimilars is rising in many specialties and across channels where biosimilars have been introduced more recently. Biologics has been a rapidly evolving area within the biotechnology sector. The treatment of cancers, diabetes, and autoimmune diseases account for more than 60% of the biologics market, making it highly expensive and increasing daily. As per the World Health Organization (WHO), such prices limit healthcare systems from providing affordable and population-wide access to such medicines.
One way to combat the limitations for the use of biologicals and the subsequent pressure on healthcare budgets is to introduce biosimilars where the patents and exclusivity periods of the originator biologicals have expired. By 2018, biologicals worth more than USD 68 billion in annual sales lost patent protection. A 20% discount could save USD 14 billion, while a 30% or 40% discount could save USD 20 billion or USD 27 billion, respectively. By 2025 several biologic patents will have expired in many countries, which could translate into an opportunity to develop new biosimilars. Europe can be seen as a key region with more opportunities to be explored in the biosimilar contract manufacturing market.
Robust Pipeline of Biosimilars Boosting Contract Manufacturing
The global biopharmaceutical industry is being expanded by many new products, players, and production facilities thanks to biosimilars. With this, the number of approved and investigational biosimilars is increasing. The competition among biosimilars (including their reference products) will thus rise dramatically in the upcoming years. This includes several developers focusing on biosimilars of many of the same reference products.
Biosimilars have recently been introduced in new therapeutic segments, with reimbursement models continuing to evolve. The biosimilar pipeline is rapidly progressing and growing, with more products and companies getting involved in the manufacturing process. Biosimilars observed sustained growth in 2019, with an average growth of 20% per year. This growth is increasing at an average of 27% per year in the last five and half years.
With several commercially-viable biosimilars lacking product protection and approaching patent expiry, there are currently multiple biosimilars in the pipeline. The number of biosimilars in the pipeline, of which most are still in development, targeting the same popular reference products, has risen in the past 18 months with an average of over 50% yearly. This high growth rate in the pipeline of biosimilars is reflected in the growth of biosimilar numbers targeting other less popular reference product targets. This growth in the number of biosimilars in the development targeting the same reference products will likely continue in the short term in coming years, as more current biosimilar companies are extending their portfolios of products in development and new developers continue to enter the field.
INSIGHTS BY SOURCE
Biosimilars are developed and manufactured using mammalian and non-mammalian cell lines. The mammalian cell lines segment dominated the global biosimilar contract manufacturing market with a share of around 71% and is also the fast-growing segment. The production of biosimilars, generation of manufacturing cell lines, and optimization of manufacturing scale-up require tight control conditions and detailed analytics to ensure the biosimilar composition profile fits within the specifications of originators. For the generation of proteins for discovery research and biotherapeutic application, mammalian cell recombinant expression can help produce proteins that correctly mimic properties in a human patient.
The global non-mammalian biosimilar contract manufacturing market is growing at a CAGR of 15.54%. Non-mammalian products include biotherapeutics developed for microbial sources. The source of microbial systems is commonly used for generating recombinant protein therapeutics. Around 650 protein drugs have been approved globally, with about 400 derived from recombinant microbial technologies.
INSIGHTS BY SCALE OF OPERATION
Based on the scale of operation, the global biosimilar contract manufacturing market is segmented into commercial and research segments. In 2021, commercial accounted for the share of 85.73% in the global biosimilar contract manufacturing market. With the emergence of various chronic inflammatory conditions, cancers, autoimmune diseases, and others, there has been a growing demand for developing novel biosimilars.
Several biosimilars are in the pipeline. Due to the short span and urgency of biosimilars, researchers are working to ensure that the biosimilar can be reliably replicated at a scale for clinical trials and then again at an even greater scale for mass production. Contract manufacturing is witnessing a growing uptake because biosimilar drugs are approaching the commercial scale and entering the clinical pipeline. Even though they have well-established GMP-grade facilities, larger biopharma companies prefer to outsource manufacturing to cut costs. Contract manufacturers utilize cell-culture and microbial technologies to provide manufacturing services on a clinical and commercial scale. As a result, the contract manufacturing of biosimilars for various research activities is increasing and contributing to the growth of the research segment.
INSIGHTS BY PRODUCT
Contract manufacturing activities can be broadly divided into APIs manufacturing and FDF manufacturing. In 2021, the finished dosage form (FDF) accounted for 52.88% of the global biosimilar contract manufacturing market. An FDF is a drug product that has undergone all the production steps, including manufacturing, testing, and approval, before being delivered to the public. The FDF is an essential stage in the product life cycle, and it can only be accomplished if the pharmaceutical company's or outsourced manufacturing organization's manufacturing facilities meet high standards. Companies that do not have a standard manufacturing facility for the production of FDFs license for this primary reason.
APIs contract manufacturing shows the development of drugs with the help of contract manufacturing by outsourcing other companies. The global APIs contract manufacturing market is expected to witness increased demand during the forecast period as it has access to a skilled workforce with economical costs, favorable government policies, and tax incentives. The global active pharmaceutical ingredient biosimilar contract manufacturing market was valued at USD 1.065 billion in 2021. Manufacturing APIs is a complex and specialized activity that requires integration by chemistry, biology, and engineering experts.
INSIGHTS BY INDICATION
The global biosimilar contract manufacturing market is segmented into oncology, blood disorders, inflammation & autoimmune disorders, and other indications under the indication segment. Among these, the oncology segment dominates the industry and accounts for a 33.5% share. The development of biosimilars has been closely linked between therapeutic areas, prevalence, and the cost of diseases. Immunology and oncology are therapeutic areas with a financial burden on the healthcare systems; therefore, biosimilars are highly needed. Most FDA & EMA-approved biosimilars target inflammatory conditions. This is majorly due to the growing disease and cost burden of these chronic diseases, which is boosting the development of biosimilars, as these are highly productive and available at low costs.
Europe dominates the global biosimilar contract manufacturing market, with the most significant share of 39.44% in 2021, and is expected to grow at a CAGR of 15.14% during the projected period. A well-defined regulatory framework for biosimilars and an established biosimilar industry with leading companies such as Lonza, Boehringer Ingelheim GmbH, Rentschler Biopharma SE, and others have contributed to the increasing demand for contract manufacturing of biosimilars. Germany, France, the UK, Italy, and Spain are the major countries contributing to the region's biosimilar contract manufacturing market growth.
North America accounted for the second-highest share in the global biosimilar contract manufacturing market. Significant factors contributing to its constant growth in the market include the rising popularity of treating major chronic conditions such as inflammatory and autoimmune diseases that comprise cancers, blood disorders, and others; favorable regulatory policies and guidelines. The North American biosimilar contract manufacturing market was valued at USD 626.41 million in 2021. The development of biosimilars in the region is strictly regulated. Only those presenting a totality-of-evidence dossier with highly similar physicochemical, biological, and clinical performances are endorsed by regulatory agencies as biosimilars.
APAC will likely witness the fastest growth in the global biosimilar contract manufacturing market during the forecast period. The growing patient population with major inflammatory diseases and autoimmune disorders is raising the need for biosimilars in the region. This region has the significant advantage of less expensive treatment due to the massive income of many medical travelers. Also, rapid urbanization, growing R&D expenditures, and rising biosimilar manufacturing outsourcing will contribute to its continuous market growth. In 2021, Latin America and Middle East & Africa accounted for minimal shares in the biosimilar contract manufacturing market. These regions are expected to witness slow growth in the coming years with the emergence of biosimilar manufacturers outsourcing their products to contract manufacturers. In addition, regulations are being adjusted to facilitate the manufacture and registration of biosimilars that will significantly expand in these markets.
The global biosimilar contract manufacturing market is concentrated with key players such as Samsung biologics, Lonza, and Boehringer Ingelheim GmbH. Emerging players include AbbVie, Inc., Catalent, Emergent BioSolutions, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Pfizer CentreOne, and WuXi Biologics. Most leading players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their industry share. They are majorly involved in expanding existing and new markets to serve the needs of growing customer bases and boost their production capabilities to gain end-user traction.
The emergence of several emerging players intensified the competition among vendors. Major vendors offering biosimilar contract manufacturing services are present in Europe's region, including small, mid-sized, or large companies. North America and APAC contain fewer larger players and several small and mid-sized vendors. Emerging economies that include China, India, Brazil, and Mexico will likely offer significant growth opportunities for players in the biosimilar contract manufacturing market. Major vendors are becoming more active and concentrating on more diverse contract manufacturing services as required by end-users in light of growing competition and the emergence of multiple businesses.
Recent developments In The Global Biosimilar Contract Manufacturing Market
Frequently Asked Questions
What is the projected biosimilar contract manufacturing market by 2027?
The global biosimilar contract manufacturing market was valued at USD 2.26 billion in 2021 and is expected to reach USD 5.5 billion by 2027.
What is the growth rate of the global biosimilar contract manufacturing market?
The global biosimilar contract manufacturing market share is expected to grow at a CAGR of over 16% from 2021 to 2027.
Who are the key players in the global biosimilar contract manufacturing market?
Lonza, Catalent, Thermo Fischer Scientific, FUJIFILM, and Boehringer Ingelheim International GmbH are the key players in the biosimilar contract manufacturing market.
What are the key driving factors in the biosimilar contract manufacturing market?
The rise in product launches & approvals of biosimilars, regulatory activities & policies encouraging the use of biosimilars, and patent expirations of blockbuster branded biologic drugs are key trends in the global market.
Which region dominates the global biosimilar contract manufacturing market?
Europe dominates the global biosimilar contract manufacturing market, with its most significant share in 2021. One of the major factors contributing to the growth is the rising demand for biosimilars is the growing prevalence of chronic conditions such as autoimmune disorders, cancers, diabetes, and other inflammatory conditions.
The biosimilar contract manufacturing market is expected to grow at a CAGR of approximately 16.19% from 2021 to 2027.
The following factors are likely to contribute to the growth of the biosimilar contract manufacturing market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the biosimilar contract manufacturing market and its market dynamics for 2022−2027. It covers a detailed overview of several industry growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
Other Prominent Vendors
Segmentation by Source:
Segmentation by Scale of Operation:
Segmentation by Product:
Segmentation by Indication:
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY SOURCE
4.3.2 MARKET SEGMENTATION BY SCALE OF OPERATION
4.3.3 MARKET SEGMENTATION BY PRODUCT
4.3.4 MARKET SEGMENTATION BY INDICATION
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 PREMIUM INSIGHTS
8.1 MARKET SYNOPSIS
8.1.1 MARKET SEGMENTATIONS
9 MARKET OPPORTUNITIES & TRENDS
9.1 RISE IN PRODUCT LAUNCHES & APPROVALS OF BIOSIMILARS
9.2 FAVORABLE POLICIES ENCOURAGING USE OF BIOSIMILARS
9.3 PATENT EXPIRATIONS OF BLOCKBUSTER BRANDED BIOLOGIC DRUGS
9.4 RISING POTENTIAL OF BIOSIMILARS IN EMERGING MARKETS
10 MARKET GROWTH ENABLERS
10.1 FAVORABLE PATIENT DEMOGRAPHICS WITH RISE IN DISEASE BURDEN
10.2 ROBUST PIPELINE OF BIOSIMILARS BOOSTING CONTRACT MANUFACTURING
10.3 RISING INVESTMENTS FOR DEVELOPING BIOSIMILARS
10.4 HIGH COST OF BIOLOGICS & SURGE IN DEMAND FOR BIOSIMILARS
11 MARKET RESTRAINTS
11.1 QUALITY CONTROL AND SUPPLY CHAIN ISSUES WITH CONTRACT MANUFACTURING
11.2 COMPLEXITIES & LIMITATIONS INVOLVED IN MANUFACTURING BIOSIMILARS
11.3 HIGH COST OF ESTABLISHING BIOMANUFACTURING FACILITIES
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.2.1 INSIGHTS BY SOURCE
12.2.2 INSIGHTS BY SCALE OF OPERATION
12.2.3 INSIGHTS BY PRODUCT
12.2.4 INSIGHTS BY INDICATION
12.2.5 INSIGHTS BY GEOGRAPHY
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 SOURCE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 MAMMALIAN
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MAMMALIAN: MARKET BY GEOGRAPHY
13.4 NON-MAMMALIAN
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 NON-MAMMALIAN: MARKET BY GEOGRAPHY
14 SCALE OF OPERATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 COMMERCIAL
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 COMMERCIAL: MARKET BY GEOGRAPHY
14.4 RESEARCH
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 RESEARCH: MARKET BY GEOGRAPHY
15 PRODUCT
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 FINISHED DOSAGE FORM
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 FINISHED DOSAGE FORM: MARKET BY GEOGRAPHY
15.4 ACTIVE PHARMACEUTICAL INGREDIENT
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 ACTIVE PHARMACEUTICAL INGREDIENT: MARKET BY GEOGRAPHY
16 INDICATION
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 ONCOLOGY
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 ONCOLOGY: MARKET BY GEOGRAPHY
16.4 BLOOD DISORDERS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 BLOOD DISORDERS: MARKET BY GEOGRAPHY
16.5 INFLAMMATORY & AUTOIMMUNE DISORDERS
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 INFLAMMATORY & AUTOIMMUNE DISORDERS: MARKET BY GEOGRAPHY
16.6 OTHERS
16.6.1 MARKET OVERVIEW
16.6.2 MARKET SIZE & FORECAST
16.6.3 OTHERS: MARKET BY GEOGRAPHY
17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 EUROPE: SOURCE
18.2.2 EUROPE: SCALE OF OPERATION
18.2.3 EUROPE: PRODUCT
18.2.4 EUROPE: INDICATION
18.3 KEY COUNTRIES
18.3.1 GERMANY: MARKET SIZE & FORECAST
18.3.2 FRANCE: MARKET SIZE & FORECAST
18.3.3 UK: MARKET SIZE & FORECAST
18.3.4 ITALY: MARKET SIZE & FORECAST
18.3.5 SPAIN: MARKET SIZE & FORECAST
19 NORTH AMERICA
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 NORTH AMERICA: SOURCE
19.2.2 NORTH AMERICA: SCALE OF OPERATION
19.2.3 NORTH AMERICA: PRODUCT
19.2.4 NORTH AMERICA: INDICATION
19.3 KEY COUNTRIES
19.3.1 US: MARKET SIZE & FORECAST
19.3.2 CANADA: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 APAC: SOURCE
20.2.2 APAC: SCALE OF OPERATION
20.2.3 APAC: PRODUCT
20.2.4 APAC: INDICATION
20.3 KEY COUNTRIES
20.3.1 CHINA: MARKET SIZE & FORECAST
20.3.2 SOUTH KOREA: MARKET SIZE & FORECAST
20.3.3 INDIA: MARKET SIZE & FORECAST
20.3.4 JAPAN: MARKET SIZE & FORECAST
20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 LATIN AMERICA: SOURCE
21.2.2 LATIN AMERICA: SCALE OF OPERATION
21.2.3 LATIN AMERICA: PRODUCT
21.2.4 LATIN AMERICA: INDICATION
21.3 KEY COUNTRIES
21.3.1 BRAZIL: MARKET SIZE & FORECAST
21.3.2 MEXICO: MARKET SIZE & FORECAST
21.3.3 ARGENTINA: MARKET SIZE & FORECAST
22 MIDDLE EAST & ARFICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 MIDDLE EAST & AFRICA: SOURCE
22.2.2 MIDDLE EAST & AFRICA: SCALE OF OPERATION
22.2.3 MIDDLE EAST & AFRICA: PRODUCT
22.2.4 MIDDLE EAST & AFRICA: INDICATION
22.3 KEY COUNTRIES
22.3.1 TURKEY: MARKET SIZE & FORECAST
22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
22.3.3 UAE: MARKET SIZE & FORECAST
22.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST
23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
23.2.1 LONZA IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
23.2.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
23.2.3 CATALENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
23.2.4 FUJIFILM DIOSYNTH BIOTECHNOLOGIES IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
23.2.5 THERMO FISHER SCIENTIFIC IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24 KEY COMPANY PROFILES
24.1 LONZA
24.1.1 BUSINESS OVERVIEW
24.1.2 LONZA IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24.1.3 PRODUCT OFFERINGS
24.1.4 KEY STRATEGIES
24.1.5 KEY STRENGTHS
24.1.6 KEY OPPORTUNITIES
24.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
24.2.1 BUSINESS OVERVIEW
24.2.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24.2.3 PRODUCT OFFERINGS
24.2.4 KEY STRATEGIES
24.2.5 KEY STRENGTHS
24.2.6 KEY OPPORTUNITIES
24.3 CATALENT
24.3.1 BUSINESS OVERVIEW
24.3.2 CATALENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24.3.3 PRODUCT OFFERINGS
24.3.4 KEY STRATEGIES
24.3.5 KEY STRENGTHS
24.3.6 KEY OPPORTUNITIES
24.4 FUJIFILM
24.4.1 BUSINESS OVERVIEW
24.4.2 FUJIFILM IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24.4.3 PRODUCT OFFERINGS
24.4.4 KEY STRATEGIES
24.4.5 KEY STRENGTHS
24.4.6 KEY OPPORTUNITIES
24.5 THERMO FISHER SCIENTIFIC
24.5.1 BUSINESS OVERVIEW
24.5.2 THERMO FISHER SCIENTIFIC IN BIOSIMILAR CONTRACT MANUFACTURING MARKET
24.5.3 PRODUCT OFFERINGS
24.5.4 KEY STRATEGIES
24.5.5 KEY STRENGTHS
24.5.6 KEY OPPORTUNITIES
25 OTHER PROMINENT VENDORS
25.1 ABBVIE
25.1.1 BUSINESS OVERVIEW
25.1.2 SERVICE OFFERINGS
25.2 ABZENA
25.2.1 BUSINESS OVERVIEW
25.2.2 SERVICE OFFERINGS
25.3 AGC BIOLOGICS
25.3.1 BUSINESS OVERVIEW
25.3.2 SERVICE OFFERINGS
25.4 ALCAMI
25.4.1 BUSINESS OVERVIEW
25.4.2 SERVICE OFFERINGS
25.5 ALMAC GROUP
25.5.1 BUSINESS OVERVIEW
25.5.2 SERVICE OFFERINGS
25.6 AVID BIOSERVICES
25.6.1 BUSINESS OVERVIEW
25.6.2 SERVICE OFFERINGS
25.7 BIOCON
25.7.1 BUSINESS OVERVIEW
25.7.2 SERVICE OFFERINGS
25.8 ELEMENT MATERIALS TECHNOLOGY
25.8.1 BUSINESS OVERVIEW
25.8.2 SERVICE OFFERINGS
25.9 EUROFINS SCIENTIFIC
25.9.1 BUSINESS OVERVIEW
25.9.2 SERVICE OFFERINGS
25.10 FRESENIUS KABI
25.10.1 BUSINESS OVERVIEW
25.10.2 SERVICE OFFERINGS
25.11 GOODWIN BIOTECHNOLOGY
25.11.1 BUSINESS OVERVIEW
25.11.2 SERVICE OFFERINGS
25.12 KEMWELL
25.12.1 BUSINESS OVERVIEW
25.12.2 SERVICE OFFERINGS
25.13 MABXIENCE
25.13.1 BUSINESS OVERVIEW
25.13.2 SERVICE OFFERINGS
25.14 MERCK KGAA
25.14.1 BUSINESS OVERVIEW
25.14.2 SERVICE OFFERINGS
25.15 MIDAS PHARMA
25.15.1 BUSINESS OVERVIEW
25.15.2 SERVICE OFFERINGS
25.16 NOVARTIS AG
25.16.1 BUSINESS OVERVIEW
25.16.2 SERVICE OFFERINGS
25.17 PFIZER
25.17.1 BUSINESS OVERVIEW
25.17.2 SERVICE OFFERINGS
25.18 RENTSCHLER BIOPHARMA
25.18.1 BUSINESS OVERVIEW
25.18.2 SERVICE OFFERINGS
25.19 SAMSUNG BIOLOGICS
25.19.1 BUSINESS OVERVIEW
25.19.2 SERVICE OFFERINGS
25.20 WUXI BIOLOGICS
25.20.1 BUSINESS OVERVIEW
25.20.2 SERVICE OFFERINGS
26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS
27 QUANTITATIVE SUMMARY
27.1 MARKET BY SOURCE
27.1.1 EUROPE BY SOURCE SEGMENTATION
27.1.2 NORTH AMERICA BY SOURCE SEGMENTATION
27.1.3 APAC BY SOURCE SEGMENTATION
27.1.4 LATIN AMERICA BY SOURCE SEGMENTATION
27.1.5 MIDDLE EAST & AFRICA BY SOURCE SEGMENTATION
27.2 MARKET BY SCALE OF OPERATION
27.2.1 EUROPE BY SCALE OF OPERATION SEGMENTATION
27.2.2 NORTH AMERICA BY SCALE OF OPERATION
27.2.3 APAC BY SCALE OF OPERATION SEGMENTATION
27.2.4 LATIN AMERICA BY SCALE OF OPERATION
27.2.5 MIDDLE EAST AFRICA BY SCALE OF OPERATION SEGMENTATION
27.3 MARKET BY PRODUCT
27.3.1 EUROPE BY PRODUCT SEGMENTATION
27.3.2 NORTH AMERICA BY PRODUCT SEGMENTATION
27.3.3 APAC BY PRODUCT SEGMENTATION
27.3.4 LATIN AMERICA BY PRODUCT SEGMENTATION
27.3.5 MIDDLE EAST & AFRICA BY PRODUCT SEGMENTATION
27.4 MARKET BY INDICATION
27.4.1 EUROPE BY INIDCATION SEGMENTATION
27.4.2 NORTH AMERICA BY INIDCATION SEGMENTATION
27.4.3 APAC BY INIDCATION SEGMENTATION
27.4.4 LATIN AMERICA BY INIDCATION SEGMENTATION
27.4.5 MIDDLE EAST & AFRICA BY INIDCATION SEGMENTATION
27.5 MARKET BY GEOGRAPHY
27.5.1 MAMMALIAN SEGMENT BY GEOGRAPHY
27.5.2 NON-MAMMALIAN SEGMENT BY GEOGRAPHY
27.5.3 COMMERCIAL SEGMENT BY GEOGRAPHY
27.5.4 RESEARCH SEGMENT BY GEOGRAPHY
27.5.5 FINISHED DOSAGE FORM SEGMENT BY GEOGRAPHY
27.5.6 ACTIVE PHARMACEUTICAL INGREDIENTS BY GEOGRAPHY
27.5.7 ONCOLOGY SEGMENT BY GEOGRAPHY
27.5.8 BLOOD DISORDERS SEGMENT BY GEOGRAPHY
27.5.9 INFLAMMATION & AUTOIMMUNE DISORDERS SEGMENT BY GEOGRAPHY
27.5.10 OTHERS BY GEOGRAPHY
28 APPENDIX
28.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 NUMBER OF BIOSIMILAR PRODUCT AUTHORIZATIONS IN US AND EUROPE
EXHIBIT 4 ESTIMATED PATENT EXPIRATIONS OF BIOLOGICS ACROSS VARIOUS REGIONS
EXHIBIT 5 BIOSIMILAR PIPELINE BY PHASES OF DEVELOPMENT (2013 & 2020)
EXHIBIT 6 IMPACT OF RISE IN PRODUCT LAUNCHES & APPROVALS OF BIOSIMILARS
EXHIBIT 7 LAUNCHES & APPROVALS OF BIOSIMILARS IN US (2015–2021)
EXHIBIT 8 BIOSIMILAR PRODUCT AUTHORIZATIONS IN US AND EUROPE
EXHIBIT 9 LAUNCHES OF NEW & UPCOMING BIOSIMILARS IN US
EXHIBIT 10 IMPACT OF FAVORABLE POLICIES ENCOURAGING USE OF BIOSIMILARS
EXHIBIT 11 IMPACT OF PATENT EXPIRATIONS OF BLOCKBUSTER BRANDED BIOLOGIC DRUGS
EXHIBIT 12 ESTIMATED PATENT EXPIRATIONS OF BIOLOGICS ACROSS VARIOUS REGIONS
EXHIBIT 13 IMPACT OF RISING POTENTIAL OF BIOSIMILARS IN EMERGING MARKETS
EXHIBIT 14 GROWTH OF BIOSIMILAR SHARES IN EMERGING MARKETS
EXHIBIT 15 IMPACT OF FAVORABLE PATIENT DEMOGRAPHICS WITH RISE IN DISEASE BURDEN
EXHIBIT 16 GLOBAL STATISTICS OF MAJOR AUTOIMMUNE DISEASES (2021)
EXHIBIT 17 ESTIMATED PERCENTAGE OF MAJOR CANCERS WORLDWIDE (2022)
EXHIBIT 18 IMPACT OF ROBUST PIPELINE OF BIOSIMILARS BOOSTING CONTRACT MANUFACTURING
EXHIBIT 19 BIOSIMILAR PIPELINE BY PHASES OF DEVELOPMENT (2013 & 2020)
EXHIBIT 20 PIPELINE OF BIOSIMILARS IN VARIOUS COUNTRIES OR REGIONS
EXHIBIT 21 TOP BIOSIMILAR COMPANIES WITH THEIR TOTAL & PIPELINE BIOSIMILAR PRODUCTS
EXHIBIT 22 IMPACT OF RISING INVESTMENTS FOR DEVELOPING BIOSIMILARS
EXHIBIT 23 IMPACT OF HIGH COST OF BIOLOGICS & SURGE IN DEMAND FOR BIOSIMILARS
EXHIBIT 24 CHANGE IN PRICES AFTER INTRODUCTION OF BIOSIMILAR ACCESSIBLE MARKET
EXHIBIT 25 IMPACT OF QUALITY CONTROL AND SUPPLY CHAIN ISSUES WITH CONTRACT MANUFACTURING
EXHIBIT 26 MAJOR BARRIERS TO EFFECTIVE VACCINE HANDLING AND STORAGE
EXHIBIT 27 IMPACT OF COMPLEXITIES & LIMITATIONS INVOLVED IN MANUFACTURING BIOSIMILARS
EXHIBIT 28 IMPACT OF HIGH COST OF ESTABLISHING BIOMANUFACTURING FACILITIES
EXHIBIT 29 TOP 10 GLOBAL MANUFACTURING HUBS
EXHIBIT 30 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 31 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE
EXHIBIT 32 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION
EXHIBIT 33 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT
EXHIBIT 34 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION
EXHIBIT 35 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY
EXHIBIT 36 FIVE FORCES ANALYSIS 2021
EXHIBIT 37 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 38 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE
EXHIBIT 39 NUMBER OF BIOSIMILARS IN PIPELINE DISTRIBUTED BY PHASE AND PRODUCTION TECHNOLOGY 2019
EXHIBIT 40 VARIOUS CELL LINE EXPRESSION SYSTEMS OFFERED BY CONTRACT MANUFACTURERS
EXHIBIT 41 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE: INCREMENTAL GROWTH
EXHIBIT 42 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE: ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL MAMMALIAN BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 ORIGINATORS AND PRODUCTS OF MAMMALIAN-BASED BIOSIMILAR TARGETS DISTRIBUTED BY PHASE
EXHIBIT 45 GLOBAL MAMMALIAN BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 47 GLOBAL NON-MAMMALIAN BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 ORIGINATORS AND PRODUCTS OF MICROBIAL-BASED BIOSIMILAR TARGETS DISTRIBUTED BY PHASE
EXHIBIT 49 GLOBAL NON-MAMMALIAN BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 50 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 51 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 52 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION
EXHIBIT 53 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION: INCREMENTAL GROWTH
EXHIBIT 54 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION: ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL COMMERCIAL BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL COMMERCIAL BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 58 GLOBAL RESEARCH BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL RESEARCH BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 61 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 62 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT
EXHIBIT 63 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT: INCREMENTAL GROWTH
EXHIBIT 64 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT: ABSOLUTE GROWTH
EXHIBIT 65 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY FINISHED DOSAGE FORM: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY FINISHED DOSAGE FORM 2021–2027 ($ MILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 68 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY ACTIVE PHARMACEUTICAL INGREDIENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY ACTIVE PHARMACEUTICAL INGREDIENT 2021–2027 ($ MILLION)
EXHIBIT 70 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 71 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 72 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION
EXHIBIT 73 EMA- & FDA-APPROVED BIOSIMILARS BY THERAPEUTIC AREA (2019)
EXHIBIT 74 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION: INCREMENTAL GROWTH
EXHIBIT 75 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION: ABSOLUTE GROWTH
EXHIBIT 76 GLOBAL ONCOLOGY BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 EXPIRED PATENTS OF ONCOLOGY BIOLOGIC DRUGS IN US & EUROPE
EXHIBIT 78 FDA-APROVED BIOSIMILARS FOR ONCOLOGY TREATMENT
EXHIBIT 79 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY ONCOLOGY 2021–2027 ($ MILLION)
EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 81 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY BLOOD DISORDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY BLOOD DISORDERS 2021–2027 ($ MILLION)
EXHIBIT 83 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 84 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INFLAMMATORY & AUTOIMMUNE DISORDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 85 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INFLAMMATORY & AUTOIMMUNE DISORDERS 2021–2027 ($ MILLION)
EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 87 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY OTHER INDICATIONS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 88 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY OTHER INDICATIONS 2021–2027 ($ MILLION)
EXHIBIT 89 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 90 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 91 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY
EXHIBIT 92 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY: KEY COUNTRIES (2021)
EXHIBIT 93 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 94 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 95 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET: KEY COUNTRIES (2021)
EXHIBIT 96 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 97 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 98 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 99 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 100 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 101 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 102 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 103 GERMANY BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 104 FRANCE BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 105 UK BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 106 ITALY BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 107 SPAIN BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 108 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: KEY COUNTRIES (2021)
EXHIBIT 109 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 110 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 111 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 112 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 113 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 114 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 115 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 116 US BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 117 CANADA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 118 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET: KEY COUNTRIES (2021)
EXHIBIT 119 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 120 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 121 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 122 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 123 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 124 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 125 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 126 CHINA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 127 SOUTH KOREA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 128 INDIA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 129 JAPAN BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 130 AUSTRALIA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 131 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: KEY COUNTRIES (2021)
EXHIBIT 132 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 133 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 134 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 135 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 136 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 137 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 138 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 139 BRAZIL BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 140 MEXICO BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 141 ARGENTINA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 142 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: KEY COUNTRIES (2021)
EXHIBIT 143 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 144 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 145 INCREMENTAL GROWTH BY SOURCE 2021 & 2027
EXHIBIT 146 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 147 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 148 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
EXHIBIT 149 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 150 TURKEY BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 151 SAUDI ARABIA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 152 UAE BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 153 SOUTH AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET 2021–2027 ($ MILLION)
EXHIBIT 154 LONZA: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 155 LONZA: REVENUE BY BUSINESS SEGMENT 2020–2021 ($ MILLION)
EXHIBIT 156 LONZA: TOTAL R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 157 LONZA: REVENUE BY GEOGRAPHIC REGION 2020–2021 ($ MILLION)
EXHIBIT 158 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 159 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE BY BUSINESS SEGMENT 2019–2021 ($ BILLION)
EXHIBIT 160 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: TOTAL R&D EXPENDITURE 2019–2021 ($ BILLION)
EXHIBIT 161 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE BY GEOGRAPHIC REGION 2019–2021 ($ BILLION)
EXHIBIT 162 CATALENT: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 163 FUJIFILM: TOTAL REVENUE 2018–2020 ($ BILLION)
EXHIBIT 164 FUJIFILM: REVENUE BY BUSINESS SEGMENT 2019–2020 ($ BILLION)
EXHIBIT 165 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 166 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2020–2021 ($ MILLION)
EXHIBIT 167 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 168 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2021 ($ MILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 PATENT EXPIRATION OF MAJOR BIOLOGICS BY THERAPEUTIC AREA
TABLE 4 NUMBER OF BIOSIMILARS IN DEVELOPMENTAL PIPELINE (2017 & 2019)
TABLE 5 BIOSIMILARS APPROVED BY FDA & EMA (BY INDICATION)
TABLE 6 LONZA: MAJOR PRODUCT OFFERINGS
TABLE 7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: MAJOR PRODUCT OFFERINGS
TABLE 8 CATALENT: MAJOR PRODUCT OFFERINGS
TABLE 9 FUJIFILM: MAJOR PRODUCT OFFERINGS
TABLE 10 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 11 ABBVIE: MAJOR SERVICE OFFERINGS
TABLE 12 ABZENA: MAJOR SERVICE OFFERINGS
TABLE 13 AGC BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 14 ALCAMI: MAJOR SERVICE OFFERINGS
TABLE 15 ALMAC GROUP: MAJOR SERVICE OFFERINGS
TABLE 16 AVID BIOSERVICES: MAJOR SERVICE OFFERINGS
TABLE 17 BIOCON: MAJOR SERVICE OFFERINGS
TABLE 18 ELEMENT MATERIALS TECHNOLOGY: MAJOR SERVICE OFFERINGS
TABLE 19 EUROFINS SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 20 FRESENIUS KABI: MAJOR SERVICE OFFERINGS
TABLE 21 GOODWIN BIOTECHNOLOGY: MAJOR SERVICE OFFERINGS
TABLE 22 KEMWELL: MAJOR SERVICE OFFERINGS
TABLE 23 MABXIENCE: MAJOR SERVICE OFFERINGS
TABLE 24 MERCK KGAA: MAJOR SERVICE OFFERINGS
TABLE 25 MIDAS PHARMA: MAJOR SERVICE OFFERINGS
TABLE 26 NOVARTIS AG: MAJOR SERVICE OFFERINGS
TABLE 27 PFIZER: MAJOR SERVICE OFFERINGS
TABLE 28 RENTSCHLER BIOPHARMA: MAJOR SERVICE OFFERINGS
TABLE 29 SAMSUNG BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 30 WUXI BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 31 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 32 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 33 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 34 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 35 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 36 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 37 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 38 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 39 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 40 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 41 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 ($ MILLION)
TABLE 42 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SOURCE 2021–2027 (%)
TABLE 43 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 44 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 45 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 46 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 47 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 48 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 49 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 50 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 51 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 52 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 53 MIDDLE EAST AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 ($ MILLION)
TABLE 54 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021–2027 (%)
TABLE 55 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 56 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 57 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 58 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 59 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 60 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 61 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 62 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 63 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 64 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 65 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 ($ MILLION)
TABLE 66 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY PRODUCT 2021–2027 (%)
TABLE 67 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 68 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 69 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 70 EUROPE BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 71 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 72 NORTH AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 73 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 74 APAC BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 75 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 76 LATIN AMERICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 77 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 ($ MILLION)
TABLE 78 MIDDLE EAST & AFRICA BIOSIMILAR CONTRACT MANUFACTURING MARKET BY INDICATION 2021–2027 (%)
TABLE 79 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 80 GLOBAL BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 81 MAMMALIAN SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 82 MAMMALIAN SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 83 NON-MAMMALIAN SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021– 2027 ($ MILLION)
TABLE 84 NON-MAMMALIAN SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 85 COMMERCIAL SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 86 COMMERCIAL SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 87 RESEARCH SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 88 RESEARCH SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 89 FINISHED DOSAGE FORM SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 90 FINISHED DOSAGE FORM SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 91 ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 92 ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 93 ONCOLOGY SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 94 ONCOLOGY SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 95 BLOOD DISORDERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 96 BLOOD DISORDERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021– 2027 (%)
TABLE 97 INFLAMMATION & AUTOIMMUNE DISORDERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 98 INFLAMMATION & AUTOIMMUNE DISORDERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 99 OTHERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 100 OTHERS SEGMENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021–2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
